Monday, July 11, 2016
Icon, a global provider of drug development solutions and services to the pharmaceutical, biotechnology and medical device industries, has agreed, subject to certain customary closing conditions (including applicable regulatory approvals), to acquire Clinical Research Management (ClinicalRM). The acquisition will enhance Icon’s ability to access the market for government sponsored research and further enhances Icon’s capabilities in the areas of Vaccines and Infectious Disease.
CRO Clinical Research Management was awarded a contract by the Department of Health and Human Services, NIH, Division of Microbiology and Infectious Diseases (DMID) of the National Institute of Allergy and Infectious Diseases (NIAID). The intent of the award is to provide a broad spectrum of services for the design and conduct of phase I-IV clinical trials and clinical studies focused on the screening, diagnosis, treatment, prevention and control of sexually transmitted infections within the Sexually Transmitted Infections Clinical Trials Group (STI CTG) Program.